Chimeric Therapeutics Ltd has released a press release.
Chimeric Therapeutics: Half Year Report and Appendix 4D 31 December 2024
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- $4.0m Non-Dilutionary Funding
- Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
- Chimeric receives $4.17m R&D tax incentive
- AGM Presentation and CEO Appointment
- Reinstatement to Official Quotation
Later from Chimeric Therapeutics
- Suspension from Quotation
- Chimeric announces intention to undertake Entitlement Offer
- Reinstatement to Quotation
- Entitlement Offer to raise approximately $3.2 million
- Prospectus
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics